Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04822181 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT04822181 · ClinicalTrials.gov record · last posted 2026-08-04

Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)

Study acronym: ESSENCE
StatusActive, Not Recruiting
PhasePhase 3
Started2021-04-01
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
Semaglutide is a medicine studied in patients with NASH. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabetes in many countries. Participants will either get semaglutide or a dummy medicine - which treatment participants get is decided by chance. Participants will need to inject themselves with medicine under the skin. Participants will need to do this once a week. The study will last for about 5 years. Participants will have up to 21 clinic visits and 9 phone calls with the clinical staff during the study. Some of the clinic visits may be spread over more than one day. Participants with other chronic liver diseases cannot take part in this study. Women cannot take part in the study if they are pregnant, breast-feeding or plan to become pregnant during the study period.

Protocol amendment history 1 change detected by DataLookout

2026-04-08
minor
Trial sites expanded: 552 → 556 locations
Trial Details
NCT Number NCT04822181
Lead Sponsor Novo Nordisk A/S
Conditions Non-alcoholic Steatohepatitis
Enrollment 1,205 participants
Start Date 2021-04-01
Primary Completion 2029-04-25 (estimated)
Study Completion 2029-04-25 (estimated)
Updated on ClinicalTrials.gov 2026-08-04